Asian Diabetes Surgery Study (ADSS): Clinical Predictor for the Success of Metabolic Surgery
ADSS
Asian Diabetes Surgery Study:A Multi-institutes Prospective Study Clinical Predictor for the Successful Treatment of Type 2 Diabetes After Metabolic Surgery
1 other identifier
observational
200
1 country
2
Brief Summary
Type 2 Diabetes Mellitus (T2DM) is a serious health problem that has increased dramatically worldwide due to the high and increasing prevalence of obesity. Medical management of T2DM is of limited success. Because not well controlled T2DM patients are in high risk of blindness, cardiovascular accident and end staged disease, T2DM has become a major health burden for society. Recent data on the relative effectiveness of gastrointestinal metabolic surgery played as bariatric surgery in the remission of T2DM, suggests that it may be significantly more effective than current medical treatment. In considering that less than half of the T2DM patients can achieve satisfactory treatment goal under current medical treatment, gastrointestinal metabolic surgery shall play an important role in T2DM treatment in the future. However, the indication for metabolic surgery and clinical predictors of success are not clear now. These clinical predictors can help us to choose appropriate not-well controlled T2DM patients to receive metabolic surgery and reduce dverse health outcomes in those patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2011
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2011
CompletedFirst Submitted
Initial submission to the registry
March 2, 2011
CompletedFirst Posted
Study publicly available on registry
March 18, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2013
CompletedMarch 18, 2011
March 1, 2011
1.2 years
March 2, 2011
March 17, 2011
Conditions
Study Arms (1)
Diabetes group I
metabolic surgery, laparoscopicly
Eligibility Criteria
1. Age between 18 to 65. 2. Type 2 DM \> 6 months, HbA1C\>7.0% under treatment 3. Body mass index \>25 kg/m2 4. could follow up
You may qualify if:
- Age between 18 to 65.
- Type 2 DM \> 6 months, HbA1C\>8.0% under treatment
- Body mass index \>25 kg/m2
- could follow up
You may not qualify if:
- Age \<18 or \>65
- HbA1C \< 7%
- BMI \< 25 kg/m2
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Min sheng general hospital
Taoyuan, Taiwan
MinSheng Genral Hospital
Taoyuan District, Taiwan
Biospecimen
Serum stored at a -85 ℃ refrigerator
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jun Juin Tsou, university
Metabolic surgery center,Minsheng general hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
March 2, 2011
First Posted
March 18, 2011
Study Start
January 1, 2011
Primary Completion
March 1, 2012
Study Completion
December 1, 2013
Last Updated
March 18, 2011
Record last verified: 2011-03